Generic policy in Bulgaria: a policy of failure or success?

References

• Ess SM, Schneeweiss S, Szucs TD. European healthcare policies for controlling drug expenditure. Pharmacoeconomics. 2003;21(2):89–103.
   PubMed Web of Science ®Google Scholar
• Jönsson B. Pricing and reimbursement of pharmaceuticals in Sweden. Pharmacoeconomics. 1994;6(S1):51–60.
   PubMed Web of Science ®Google Scholar
• Rigter H. Recent public policies in the Netherlands to control pharmaceutical pricing and reimbursement. Pharmacoeconomics. 1994;6(S1):15–21.
   PubMed Web of Science ®Google Scholar
• Fattore G, Jommi C. The new pharmaceutical policy in Italy. Health Policy. 1998;46:21–41.
   PubMed Web of Science ®Google Scholar
• UK Department of Health. Options for the future supply and reimbursement of generic medicines for the NHS: a discussion paper [Internet]. London: Department of Health; 2001 [updated 2001 Jul 23; cited 2016 Apr 16]. Available from: http://webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4019990.pdf.
   Google Scholar
• Giuliani G, Selke G, Garattini L. The German experience in reference pricing. Health Policy. 1998;44:73–85.
   PubMed Web of Science ®Google Scholar
• Mossialos E, Le Grand J. Cost containment in the EU: an overview. In: Mossialos E, Le Grand J, editors. Health care and cost containment in the European Union. Aldershot: Ashgate; 1999. p. 128–129.
   Google Scholar
• Hensley S. Another war on drugs: European countries turn to ‘reference pricing’ in battle against soaring cost of pharmaceuticals. Mod Healthc. 1999;29:38–39.
   Google Scholar
• Garattini L, Tediosi F. A comparative analysis of generic markets in five European countries. Health Policy. 2000;51:149–162.
   PubMed Web of Science ®Google Scholar
• Tele P, Groot W. Cost containment measures for pharmaceuticals expenditure in the EU countries: a comparative analysis. Open Health Serv Pol J. 2009;2:71–83.
   Google Scholar
• Kaló Z, Holtorf AP, Alfonso-Cristancho R, et al. Need for multicriteria evaluation of generic drug policies. Value Health. 2015;18(2):346–351.
   PubMed Web of Science ®Google Scholar
• Cameron A, Ewen M, Ross-Degnan D, et al. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet. 2009;373:632–635.
   PubMed Web of Science ®Google Scholar
• Kanavos P. Financing pharmaceuticals in transition economies. Croat Med J. 1999;40:244–259.
   PubMed Web of Science ®Google Scholar
• Cameron A, Laing R. Cost savings of switching private sector consumption from originator brand medicines to generic equivalents. Background Paper 35 [Internet]. Geneva: World Health Organization; 2015; c2010 [cited 2015 Apr 16]. Available from: http://www.who.int/healthsystems/topics/financing/healthreport/35MedicineCostSavings.pdf.
   Google Scholar
• Dylst P, Simoens S. Generic medicine pricing policies in Europe: current status and impact. Pharmaceuticals. 2010;3:471–481.
   Google Scholar
• van de Hoven A. Improving access to generic & biosimilar medicines in Bulgaria and in the EU [Presentation] Nov 14. Sofia (Bulgaria): European Generic Medicines Associations (EGA); 2013. Available from: http://static.framar.bg/filestore/Adrian_van_den_Hoven.pdf.
   Google Scholar
• Kanavos P. Pharmaceutical coverage and resource allocation: lessons for the US from pharmaceutical policies in the UK. Paper presented at: Annual Research Meeting of the Academy of Health Services Research and Health Policy; 2002 June 23–25; Washington, DC, USA.
   Google Scholar
• Hassali MA, Wong ZY. Challenges of developing generics substitution policies in low- and middle-income countries (LMICs). GaBI J. 2015;4(4):171–172.
   Google Scholar
• Manova M, Stoimenova A, Clerfeuille F, et al. Impact of the generic competition on usage and process of cardiovascular medicines on the Bulgarian pharmaceutical market. J Public Health. 2011;19(1):91–100.
   Google Scholar
• Zeng W. A price and use comparison of generic versus originator cardiovascular medicines: a hospital study in Chongqing, China: BMC Health Serv Res [Internet]. 2013 [cited 2016 Apr 16];13:390. Available from: http://bmchealthservres.biomedcentral.com/articles/10.1186/1472-6963-13-390.
   Google Scholar
• Manova M, Stoimenova A, Savova A, et al. Utilization and price trends in some reimbursed cardiovascular medicines. Biotechnol Biotechnol Equip. 2011;25(2):2424–2431.
   Web of Science ®Google Scholar
• Petrova G, Manova M, Stoimenova A, et al. Cardiovascular medicines prescribing in Bulgaria. Compt Rend Acad Bulg Sci. 2011;64(2):285–292.
   Web of Science ®Google Scholar
• Ministry of Health of the Republic of Bulgaria. National drug policy [Internet]. Sofia: Ministry of Health; 2015; c2015 [ cited 2015 Apr 16]. Available from: http://www.mh.government.bg. Bulgarian.
   Google Scholar
• Law on Medicinal Products in Human Medicine. State Gazette [Internet]. №15 [cited 2013 Feb 15]. Available from: http://en.bda.bg/index.php?option=com_content&view=article&id=21&Itemid=10.
   Google Scholar
• Legislatiive Document. Ordinance № 27 of 15 Jun 2007 for the requirements and documentation for authorization and registration of medicinal products. Bulgarian State Gazette [Internet]. №54; 2007 [cited 2015 Apr 16]. Available from: http://www.bda.bg/index.php?option=com_content&view=article&id=68&Itemid=60&lang=bg.
   Google Scholar
• Legislatiive Document. Ordinance № 4 of 4 Mar 2009 on the conditions for prescribing and dispensing of medicinal products. Bulgarian State Gazette [Internet]. №21; 2009 [cited 2015 Apr 2016 ]. Available from: http://www.mh.government.bg/articles.aspx?lang=bgbg&pageid=391&categoryid=1246.
   Google Scholar
• Legislatiive Document. Ordinance on the terms, rules and procedure for and registration of prices for medicinal products. Bulgarian State Gazette [Internet]. №40; 2013 [Amended and supplemented, SG №66; 2014 Aug 8. Amended and supplemented, SG №92; 2014 Nov 7. Amended, SG №107; 2014 Dec 24. Amended and supplemented, SG № 92; 2015 Nov 27. Cited 2015 Apr 16]. Available from: http://www.ncpr.bg. Bulgarian.
   Google Scholar
• PubMed Health [Internet]. Bethesda (MD):National Center for Biotechnology Information. 2005 [cited 2016 Feb 14]. Available from: http://www.ncbi.nlm.nih.gov/pubmed.
   Google Scholar
• Embase (Excerpta Medica Database) [Internet]. Amsterdam: Elsevier B.V; 2015; c2015 [cited 2015 Apr 16]. Available from: http://www.embase.com.
   Google Scholar
• Cochrane Library [Internet]. Chichester: Wiley; 2016; c1999–2016 [ cited 2016 Feb 14]. Available from: www.cochranelibrary.com.
   Google Scholar
• Simoens S. Sustainable provision of generic medicines in Europe [Internet]. Brussels: European Generic Medicines Association; 2013 [cited 2015 Feb 25]. Available from: http://www.quotidianosanita.it/allegati/create_pdf.php?all=3090824.pdf.
   Google Scholar
• Kaplan WA, Ritz LS, Vitello M, et al. Policies to promote use of generic medicines in low and middle income countries: a review of published literature, 2000–2010. Health Policy. 2012;106(3):211–224.
   PubMed Web of Science ®Google Scholar
• King DR, Kanavos P. Encouraging the use of generic medicines: implications for transition economies. Croatian Med J. 2002;43(4):462–469.
   PubMed Web of Science ®Google Scholar
• Simoens S, De Bruyn K, Bogaert M, et al. Pharmaceutical policy regarding generic drugs in Belgium. Pharmacoeconomics. 2005;23(8):755–766.
   PubMed Web of Science ®Google Scholar
• Simoens S, De Coster S. Sustaining generic medicines markets in Europe. J Generic Med. 2006;3(4):257–268.
   Google Scholar
• Mitkova Z, Manova M, Petrova G. Impact of the generic competition on reference prices of cardiovascular medicines. Pharmacia. 2014;61(3):9–17.
   Google Scholar
• Mitkova Z, Manova М, Petrova G. Influence of the generic competition on reference prices of cardiovascular fixed dose combinations. Sci Pharmacol. 2014;2(9):27–37.
   Google Scholar